Induction of high tolerance to artemisinin by sub-lethal administration: A new in vitro model of P. falciparum

Serena De Lucia1*, Ioannis Tsamesidis2, Maria Carmina Pau3, Kristina R. Kesely4, Antonella Pantaleo3, Francesco Turrini1

1 Department of Oncology, University of Turin, Turin, Italy, 2 Department of Medicine, Section of Internal Medicine, University of Verona, Verona, Italy, 3 Department of Biomedical Sciences, University of Sassari, Sassari, Italy, 4 Department of Biochemistry, Purdue University, West Lafayette, United States of America

Current address: Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
* sdelucia@unito.it

Abstract

Artemisinin resistance is a major threat to malaria control efforts. Resistance is characterized by an increase in the Plasmodium falciparum parasite clearance half-life following treatment with artemisinin-based combination therapies (ACTs) and an increase in the percentage of surviving parasites. The remarkably short blood half-life of artemisinin derivatives may contribute to drug-resistance, possibly through factors including sub-lethal plasma concentrations and inadequate exposure. Here we selected for a new strain of artemisinin resistant parasites, termed the artemisinin resistant strain 1 (ARS1), by treating P. falciparum Palo Alto (PA) cultures with sub-lethal concentrations of dihydroartemisinin (DHA). The resistance phenotype was maintained for over 1 year through monthly maintenance treatments with low doses of 2.5 nM DHA. There was a moderate increase in the DHA IC50 in ARS1 when compared with parental strain PA after 72 h of drug exposure (from 0.68 nM to 2 nM DHA). In addition, ARS1 survived treatment physiologically relevant DHA concentrations (700 nM) observed in patients. Furthermore, we confirmed a lack of cross-resistance against a panel of antimalarials commonly used as partner drugs in ACTs. Finally, ARS1 did not contain PfK13 propeller domain mutations associated with ART resistance in the Greater Mekong Region. With a stable growth rate, ARS1 represents a valuable tool for the development of new antimalarial compounds and studies to further elucidate the mechanisms of ART resistance.

Introduction

Plasmodium falciparum is the most lethal of the malaria known to infect humans [1], and was responsible for nearly 212 million new cases and 429,000 deaths in 2016 [2]. Artemisinin derivatives (ART) represent the most widely used anti-malarial drugs. Derived from the plant Artemisia annua, ART contain an endoperoxide ring essential for its potent and rapid antimalarial activity [3, 4]. Although ring-stage parasites are most sensitive to drug treatment, ART
are active against all asexual stages of parasite development [5]. Unfortunately, the use of ART as mono-therapies has contributed to the increase and spread of artemisinin resistant parasites, and remains a major threat for malaria control efforts in South East Asia [6]. Although artemisinin derivatives are now only used in combination with slow-acting partner drugs as ACTs to deter drug—resistance, however, resistance to partner drugs has been detected [7, 8], further necessitating the development of new and effective antimalarials [9, 10].

Artemisinin resistance is defined by a delay in parasite clearance following 3 days (DPC3) of treatment with ACTs, but, many times, parasites become resistant to the partner drug in addition to ART [11]. Partner drug resistance is characterized by recrudescence of the infection after 28 or even 42 days following ACT treatment [12]. For this reason, malaria parasite are evaluated 3 days and 28 days following treatment for a lack of adequate clinical and parasitological response at day 28 (ACPR28) [13, 14, 15, 16]. ART rely on their rapid conversion to reactive free radicals for potent antimalarial activity. However, their very short clearance half-life (~1h) combined with under dosage of infected patients and incomplete drug treatment may contribute to the occurrence and spread of ART resistance [17, 18, 19]. Exacerbating the situation, patients frequently undergo incomplete treatment [20, 21]. ART resistant parasites may have acquired the ability to survive under the sub-lethal drug concentrations or insufficient exposure to artemisinin, similar to that seen in bacterial resistance to antimicrobial agents [22, 23, 24].

Stable ART resistant strains of *P. falciparum*, have been obtained from infected patients while others have been manipulated to induce artemisinin resistance by subjecting parasites to increasing concentrations of DHA *in vitro* [22, 25, 26, 27]. The heterogeneity and number of factors that can contribute to ART resistance have been evidenced by the amount of studies performed in a similar manner *in vitro* [28, 29]. Interestingly, the over-expression of *P. falciparum* malaria genes related to cell repair mechanisms have been identified and not only support research demonstrating ART generate free radicals for antimalarial activity, but also the rapid response of parasites to increasing drug pressure by inducing a series of protective and repair mechanisms [30, 31].

Laboratory-adapted strains of *P. falciparum* contain phenotypes uncharacteristic to those found in clinical isolates, or parasite resistance found in patients [32]. While all these strains may be ART resistant, not all artemisinin resistance phenotypes are the same. In addition, the type manipulation used to induce artemisinin resistance *in vitro* can induce a similar uncharacteristic phenotype. For example, a large number of dormant parasites are induced by short treatments with high DHA concentrations, but evidence of similarly dormant parasites during infection is lacking [33].

Finally, it has been reported that mutations in the *P. falciparum* kelch-13 propeller (*Pfk13*) gene are associated with ART resistant malaria in the Greater Mekong Sub-region and in China-Myanmar [34, 35, 36]. It has been suggested this resistance is due to the dysregulation of Phosphatidylinositol 3-phosphate metabolism, which is critical for parasite survival [37, 38, 39]. Although ACTs have been widely used for over a decade, no *Pfk13* propeller mutations associated with ART resistance have been reported for in African *P. falciparum* populations [40, 41]. These results strongly support the involvement of multiple factors with delayed parasite clearance after ACT treatment and the importance of preventing parasite tolerance to the partner drug.

With these findings in mind, we set out to select an artemisinin resistant strain by exposing parasites to sub-lethal DHA concentrations and then progressively shortening the time intervals between drug treatments. Cultures were monitored, taking great care to prevent the accumulation of dormant parasites. We now present a novel *P. falciparum* artemisinin resistant strain (ARS1) that possess a high tolerance against sub-lethal DHA concentrations and this
stable strain will help elucidate ART resistance mechanisms and direct efforts to test new antimalarial compounds.

Materials and methods

Plasmodium falciparum cultures

Three P. falciparum parasites strains were used in this study and obtained from field isolate. The Palo Alto (PA) strain was isolated from a Ugandan patient and is considered as a reference strain due to its high genetic stability. PA has historically been used as a strain to study drug susceptibility in P. falciparum in vitro [42]. The FCR3 strain derived from Gambian parasites and is genetically related with PA and it has been used to generate a chloroquine (CQ) and pyrimethamine (PM) resistant strain [22, 42]. The HB3A parasites strain derived from Honduras and has been used to induce chloroquine resistance [43, 22].

Plasmodium falciparum-infected red blood cell (I-RBC) culture maintenance

P. falciparum strains PA, FCR3, HB3A and the ARS1 strain, selected in this study (mycoplasma free), were maintained in culture with fresh red blood cells RBCs (Rh+) from healthy volunteers of both sexes. Human blood samples were used only to sustain the parasites in vitro cultures. Blood samples used to perform the present study were obtained from Banca del sangue C/O Ospedale Molinette, Torino with written informed consent. This study was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. No ethical approval has been requested. RBCs were separated from plasma and leukocytes by three washes in RPMI 1640 medium containing 25 mM HEPES (R5886 Sigma Aldrich), and then resuspended in RPMI 1640 + HEPES medium supplemented with 200 mM L-glutamine (59202C Sigma Aldrich), 2 mM glucose and gentamicin (80 mg/mL). For complete growth medium, this was further supplemented with 1% SAG-M solution, (150 mM NaCl, 1.25 mM adenine, 30 mM glucose, 145 mM mannitol) and heat-inactivated human serum. I-RBC cultures were maintained at 2–5% parasitemia (1% hematocrit) at 37˚C in an air/CO₂-atmosphere of 95/5% (vol/vol). All assays were performed at this parasitemia and hematocrit unless otherwise described.

Cultures were synchronized weekly by Percoll separation [44] or 5% sorbitol solution treatment [45]. The synchronization process did not influence the generation or phenotype of the artemisinin resistant strain. Parasite viability and parasitemia were monitored by Diff-Quick stained thin blood smears and light microscopy (Carl Zeiss Standard Microscope Lamphouse 467230). Parasitemia was defined as the number of parasites/number of RBCs counted, for a total of 5000 RBCs. Two thin smears per condition were counted 3 separate times by each of three operators.

Selection of artemisinin resistant strain 1 (ARS1) following DHA treatment

DHA (D7439 Sigma-Aldrich) was suspended in sterile dimethyl sulfoxide (DMSO) and subsequently diluted in RPMI 1640 + HEPES prior to I-RBC treatment.

For the first week (D1 –D7): i) synchronous cultures of PA, FCR3 and HB3A were supplemented daily with three concentrations of DHA (1.25, 2.5 and 5 nM) along with an untreated control. For cultures with a percentage of viable parasites lower than 1%, the daily treatments were stopped and only re-applied with a parasitemia of greater than 2.5%. ii) Before every new
treatment, I-RBC cultures were washed once in RPMI 1640 + HEPES and resuspended in fresh growth medium containing the same concentration of DHA.

For the next 7 weeks (D8 –D54): i) PA, FCR3 and HB3A were synchronized with 80% Percoll every 7–8 days, ii) treated with their respective concentration of DHA once a week (the day following Percoll synchronization), iii) the growth medium was changed every 24 h. Parasitemia was determined every day from the start of the study. When cultures were completely devoid of viable parasites for at least 7 days (analysing two thin smears every day), the cultures were considered parasite free. Fig 1 demonstrates parasite morphology from D0 to D54 of the parental PA strain and the surviving ARS1 strain with the average parasitemia reported as previously described with two operators and as a percent of the untreated control. To maintain the ARS1 strain selected from PA: i) ARS1 cultures were synchronized every 7 days with 80% Percoll to isolate trophozoite stage parasites and treated with Sorbitol 5% 24 h later to isolate ring stage parasites; ii) cultures were treated with 2.5 nM of DHA monthly at ring stage 24 h following sorbitol synchronization; iii) parasite cultures were incubated with DHA for 48 h and then replaced with fresh growth medium which was changed every 48 h; iv) this monthly DHA treatment was continued for over 1-year period.

Analysis of long-term treatment of strains PA and ARS1 with repeated DHA treatments

PA and ARS1 were treated with 1.25 and 2.5 nM DHA, respectively every 48 h for a total of 144 h in order to evaluate the PA and ARS1 behaviour assessed with different frequency DHA pressure (Fig 2) or with 2 nM DHA every 12 or 24 h for a 72 h. Parasitemia was determined as previously described.

Analysis of DHA’s effect on parasite maturation and death

PA and ARS1 ring stage cultures were treated with 0.6, 1.25, 2.5, 5 and 10 nM of DHA and evaluated at 24 and 48 h following drug addition. The effect of DHA treatment on *P. falciparum* maturation and death was evaluated by determining the parasitemia of each maturation stages: ring, trophozoite and schizont, and for intracellular dead parasites (pyknotic) in both DHA-treated and untreated control cultures. The percentage of each stage of live parasite and the number of dead parasites present in DHA treated cultures were expressed as the % parasitemia relative to the untreated cultures.

Rings-stage Survival Assay (RSA 0-3h)

The *in vitro* RSA 0-3h assay was performed using the method described by Worldwide Antimalarial Resistance Network (WWARN) (2013) and by Witkowski et al. to demonstrate the presence of reduced sensitivity to DHA in the newly selected ARS1 strain [46, 47, 48].

Briefly, the 0–3 h post invasion, ring stage parasites were exposed to 700 nM DHA for 6 h. The cultures were washed to remove the drug and then cultured with the complete medium for additional 66 h. The proportion of viable parasites was counted in the second generation parasites with normal morphology.

As described by the WHO guidelines, we calculated the survival rate (%) and the growth rate: i) the percentage of survival rate was defined as the DHA-exposed parasitemia at 72 h/non-exposed parasitemia at 72 h x 100; ii) the growth rate was defined as the non-exposed parasitemia at 72 h/the initial parasitemia at 0 h. Every thin smear were counted by microscopy via Giemsa stained evaluating a total of 10000 RBCs. Two thin smears per condition were counted 3 separate times by each of three operators. Values obtained for % of survival rate of DHA-treated are interpretable if they correspond to a growth rate ≥ 1.5%.
Synchronous ring stage cultures of strains PA, ARS1, FCR3 and HB3A were treated with DHA, mefloquine (MQ), piperaquine (PPQ), amodiaquine (AQ) and lumefantrine (LMF) and parasitemia checked every 24 h following drug treatment. The scalar concentrations of each drug included 0.6, 1.25, 2.5, 5, 10, 20 and 40 nM for DHA and 5, 10, 25, 50, 75, 100 and 200 nM for AQ, MQ, PPQ and LMF. To determine the IC$_{50}$ of each drug, cultures were treated with a

Fig 1. Response of *P. falciparum* cultures PA, FCR3, HB3A and ARS1 to DHA. PA (A), FCR3 (B), HB3A (C) and ARS1 (D) cultures were first treated daily with 1.25, 2.5 and 5 nM for 1 week and then treated weekly for 7 weeks, for a total of 54 days. Mature and immature parasites were counted. Data were normalized the parasitemia of untreated cultures determined by light microscopy of Giemsa-stained smears. Mean +/- SD of 5 independent experiments is shown.

https://doi.org/10.1371/journal.pone.0191084.g001

**IC$_{50}$ of *P. falciparum* strains treated with antimalarial drugs**

Synchronous ring stage cultures of strains PA, ARS1, FCR3 and HB3A were treated with DHA, mefloquine (MQ), piperaquine (PPQ), amodiaquine (AQ) and lumefantrine (LMF) and parasitemia checked every 24 h following drug treatment. The scalar concentrations of each drug included 0.6, 1.25, 2.5, 5, 10, 25, 50, 75, 100 and 200 nM for DHA and 5, 10, 25, 50, 75, 100 and 200 nM for AQ, MQ, PPQ and LMF. To determine the IC$_{50}$ of each drug, cultures were treated with a
Fig 2. Survival of ARS1 to increased frequency of DHA treatments every 48 h. PA and ARS1 were analysed without treatment (A) and after repeated treatments every 48 h with 1.25 nM (B) or 2.5 nM (C) DHA, by counting mature and immature parasites. Data were normalized to the control parasitemia and analysed by light microscopy of Giemsa-stained thin smears. The medium was changed every 48 h. Mean +/- SD of 5 independent experiments is shown. Significant differences between strains are indicated by (*) at p < 0.05 and (**) at p < 0.01.

https://doi.org/10.1371/journal.pone.0191084.g002
single-pulse of drug and incubated for 48 h [49, 28, 50]. IC₅₀ values were determined using ICestimator software by schizont counting (http://www.antimalarial-icestimator.net/runregression1.2.htm) [51]. The half-life was considered relevant when the R² value of the slope regression line was higher than 0.8.

**Treatments with DHA and MQ combined**

PA and ARS1 cultures were treated with DHA alone or in combination with MQ to determine if there is synergism between the two drugs and whether ARS1 is sensitive to this type of ACT. Cultures were synchronized using Percoll/5% sorbitol treatment and assay initiated at a 5% parasitemia and 1% haematocrit. IC₅₀ values determined at 24, 48 and 72 h following drug treatment: DHA (0.6, 1.25, 2.5, 5, 10, 20 and 40 nM) +/- supplemented with 5 or 10 nM MQ where described.

**P. falciparum DNA extraction**

A salting out method was used to extract parasite DNA from 100μL of I-RBCs according to standard procedures by Miller et al. [52]. Briefly, RBCs were lysed with Red Cells Lysis Buffer (RCLB) solution (Tris-HCl 10 mM, MgCl₂ 5 mM and NaCl 10 mM, pH 7.6) and the cell pellet isolated and incubated at 55˚C for 20' with White Cells Lysis Buffer (WCLB) solution (Tris-HCl 10 mM, EDTA 10 mM and NaCl 50 mM, pH 7.6) in the presence of SDS (10%) and proteinase K (20 mg/ml). The addition of a saturated salt solution (NaCl 6M) purified the DNA, which was then precipitated following the addition of isopropanol. After a 70% ethanol wash, the final DNA pellet was re-suspended in sterile H₂O and analyzed for purity by determining the ratio of absorbance at 260 and 280 nm.

**Nested-PCR analysis of strains PA and ARS1 cultures**

**Sequencing the Pfk13 propeller domain.** The P. falciparum k13 propeller domain gene was evaluated for any mutations by using nested PCR to amplify the gene previously described by Ariey et al. [32]. Amplified PCR products were purified using Exo I & Fact AP (Carlo Erba) and sequenced by Macrogen, Inc. (Netherlands). Electropherograms were visualized and analyzed with ApoE software, and alignments were performed with Muscle 3.8 software using the k13 sequence of the 3D7 clone (PF3D7_1343700) as the reference standard.

**Genotyping of msp1, msp2 and glurp with nested-PCR in PA and ARS1 strain.** The genetic characteristics of P. falciparum polymorphic genes, such as the Merozoite Surface proteins 1 and 2 (msp1 and msp2) and the Glutamate-rich protein (glurp) are commonly assessed in malaria endemic areas to discriminate recrudescence from re-infecting parasites alleles. Nested PCR was used to amplify the polymorphic regions of msp1, msp2 and glurp using family-specific primers, previously described by Snounou [53].

Briefly, in the primary reaction, oligonucleotide primers corresponded to conserved sequences within msp1 (block 2), msp2 (block 3) and glurp in the primary reaction. In the nested reaction, separate primer pairs were used that targeted the respective allelic types of msp1 (K1, MAD20, and RO33) msp2 (FC27 and IC3D7) and glurp were used [54]. The PCR products were separated on 1.5% agarose and visualized under UV illumination.

**Statistical analysis**

Error bars indicate the average ± SD. The statistical significance is estimated with two-tailed Student’s t-test performed with Microsoft Excel software.
Results

Selection for a new artemisinin resistant strain

We first performed experiments to select for artemisinin resistant parasites by experimentally determining the lowest concentration of DHA that would enable continuous culture of \textit{P. falciparum} strains PA, FCR3 and HB3A when subjected to intermittent sub-lethal drug exposure. The IC$_{50}$ values (Table 1) among the three strains revealed slight variations in sensitivity to DHA treatment. The IC$_{50}$ values of DHA in HB3A after 24 and 48 h, 2.14 and 2.27 nM, respectively, were higher than PA and FCR3 and supported by Ding et al. and Cui et al. [28, 29]. Variations in DHA sensitivity among the malaria strains can be attributed to the nature of each individual strain such as their origin, laboratory adaptation, and length of propagation [22]. In addition we obtained IC$_{50}$ values at 24 h in addition to the 48 h and 72 h due to the characteristic short half-life of DHA in patients and in cultures and to evaluate its final antimalarial efficacy [55]. These IC$_{50}$ values provided a baseline that was used to evaluate parasite sensitivity to DHA during the selection process.

For the selection process, parasite cultures were exposed to 1.25, 2.5 and 5 nM DHA every 24 h for 1 week, then washed and resuspended in drugless medium for at most 7 weeks, which included a single exposure for 24 h every week (see Materials and methods). Over time, PA cultures gained the ability to grow at a consistent rate during the weekly treatments with 1.25 nM DHA (Fig 1A). We never observed the same drug-adaptation with FCR3 or HB3A (Fig 1B and 1C). A slight growth recovery was observed during week 2 in HB3A but parasitemia declined sharply and flat lined by day 12 (Fig 1C). The higher DHA concentrations (2.5 and 5 nM) were toxic to the parasites and failed to select for any drug resistant parasites. We monitored the parasitemia of PA, FCR3, and HB3A so long as: i) there were viable parasites growing in culture and ii) the growth rate was consistent or increased over a period time. The evaluation of FCR3 and HB3A were terminated prematurely due to the complete lack of viable parasites 22 and 38 days following DHA treatment, respectively. PA was monitored for the duration of the 8-week study. After daily application of DHA during the first week, PA cultures alone contained viable parasites and the cultures appeared to be desensitized to DHA and, thus, were renamed to artemisinin resistant strain 1 (ARS1). ARS1 was evaluated for a total of 54 days after which the growth rate stabilized (the stabilization of the culture started on 32$^{nd}$

| Strain of \textit{P. falciparum} | Drug \textit{in vitro} tested | IC$_{50}$ ± SD (24 h) | IC$_{50}$ ± SD (48 h) | IC$_{50}$ ± SD (72 h) |
|---------------------------------|-------------------------------|----------------------|----------------------|----------------------|
| PA                              | DHA                           | 2.21 ± 0.4 nM        | 0.94 ± 0.1 nM        | 0.68 ± 0.2 nM        |
|                                 | MQ                            | 19.75 ± 0.3 nM       | 6.30 ± 0.1 nM        | 5.49 ± 0.92 nM       |
|                                 | PPQ                           | 20.93 ± 1.4 nM       | 19.19 ± 1.9 nM       | 16.20 ± 1.1 nM       |
|                                 | AQ                            | 21.03 ± 1.4 nM       | 15.80 ± 1.8 nM       | 14.05 ± 2.1 nM       |
|                                 | LMF                           | 22.64 ± 0.2 nM       | 18.50 ± 2.4 nM       | 17.12 ± 0.8 nM       |
| ARS1                            | DHA                           | 3.17 ± 0.5 nM        | 2.5 ± 0.2 nM         | 2.0 ± 0.3 nM         |
|                                 | MQ                            | 18.66 ± 1.8 nM       | 5.54 ± 0.7 nM        | 4.78 ± 0.6 nM        |
|                                 | PPQ                           | 19.90 ± 1.7 nM       | 11.66 ± 0.8 nM       | 8.65 ± 0.3 nM        |
|                                 | AQ                            | 19.46 ± 0.6 nM       | 14.45 ± 1.4 nM       | 14.2 ± 0.8 nM        |
|                                 | LMF                           | 21.29 ± 1.3 nM       | 17.55 ± 2.4 nM       | 16.99 ± 1.52 nM      |
| FCR3                            | DHA                           | 1.73 ± 0.6 nM        | 1.60 ± 0.3 nM        | N/D                  |
| HB3A                            | DHA                           | 2.14 ± 0.3 nM        | 2.27 ± 0.05 nM       | N/D                  |

DHA, dihydroartemisinin; MQ, mefloquine; PPQ, piperaquine; AQ, amodiaquine; LMF, lumefantrine.

All experiments were performed at least five times independently. Values are expressed in percentage of viable parasites ± SD.

https://doi.org/10.1371/journal.pone.0191084.t001
day) and parasites consistently displayed low susceptibility to the same DHA concentration used during the selection period. At 5 nM, ARS1 was still capable of maintaining a survival rate of 20%, corroborating our initial findings. It appeared that the actual selection for ARS1 was made after the first week of daily DHA treatments and the following 7 weeks of weekly 1.25 and 2.5 nM DHA treatments served to maintain this new strain with decreased sensitivity to DHA (Fig 1D). Similarly, a 40% increase in IC₅₀ was observed in ARS1 when compared with values from parental strain PA, 48 h following exposure to DHA (Table 1).

A key response of resistant parasite populations to sub-lethal drug concentrations was to recover following treatment, evidenced by an increase in parasitemia. Recovery times are specific to each strain used to the antimalarial mechanism, and so, we reduced the time interval between DHA treatments from weekly to every 48 h (Fig 2). Growth curves of ARS1 and PA are comparable in the absence of DHA (Fig 2A). Following the addition of 1.25 nM (Fig 2B) and 2.5 nM (Fig 2C) DHA treated every 48 h, only ARS1 parasitemia remained increased by 400% and 80%, respectively, from the initial value. On the other hand, PA cultures did not survive similar DHA treatments and parasitemia progressively decreased. These findings suggest that damage inflicted on ARS1 is reversible since the parasites were able to proliferate under these DHA concentrations.

While monitoring parasite recovery during the previous DHA treatments, the stage synchronicity of ARS1 decreased compared to PA. To better understand the effect of DHA on parasite maturation and death, ring-stage cultures were exposed to increasing concentrations for 48 h (Fig 3). As indicated by the relative percentage of rings, trophozoites, schizonts and dead parasites, a high number of parasites survived in ARS1 at concentrations up to 10 nM by 24 h, but decreased to levels observed in PA by 48 h. A significant amount of ARS1 parasites survived at lower DHA concentrations compared with PA. Untreated cultures were at the expected ring stage. The presence of trophozoites and schizonts in ARS1 signified parasite maturation was negatively affected and slower than untreated cultures. Overall, the percentage of immature parasites was higher in ARS1 than in PA at both 24 h (Fig 3A and 3B) and 48 h (Fig 3C and 3D). It’s possible that the DHA treated ARS1 parasites entered a state of quiescence at the ring stage or their development is delayed after 24 h which could confer the artemisinin tolerance.

This set of experiments demonstrates the ability to select for an artemisinin resistant strain from an initially sensitive to DHA by using sub-lethal concentrations. The results suggest that resistant parasites may be selected for during the first division cycles that follow sub-lethal damage exerted by DHA.

**Characterization of the newly generated ARS1 strain**

We next sought to evaluate ARS1 resilience to continuous drug pressure, so we replenished cultures with 2 nM DHA every 12 or 24 h. Replacement every 12 h was nearly lethal to ARS1, which appeared to require a longer period of time for parasite recovery between drug treatments. The decrease in parasitemia of ARS1 paralleled that of PA (Fig 4A). Replacement of DHA every 24 h reflects drug treatment schedule in patients. ARS1 survived this type of treatment, while it was lethal to PA, killing nearly 100% of parasites after 3 days of treatment (Fig 4B). On the contrary, ARS1 had a growth rate similar to that of untreated ARS1 cultures.

To maintain a drug resistance phenotype in vitro, it is critical to know the maximum time interval that can be allowed between drug treatments. This helps to evaluate a strain’s stability of drug resistance. Over 1-year period, we treated ARS1 with DHA concentrations up to 20 nM to determine the minimum concentration and maximum period of time ARS1 parasites maintain the artemisinin resistant phenotype.
After 2–3 months without DHA pressure, ARS1 lost its resistant phenotype. Parasites continue to carry the previously characterized phenotype with at least 1.25 nM DHA administered monthly. It was under monthly treatments with 2.5 nM DHA that the resistance phenotype was conserved for over 1 year. Repeated freezing and thawing of cultures using the standard protocols that employ high concentrations of glycerol did not affect this resistance either.

The Rings-stage Survival Assay (RSA0-3h) is a common assay to assess a parasite tolerance to DHA or other antimalarial drug. Briefly, parasite cultures were exposed to a single pulse of 700 nM DHA for 6 h using young ring-stage parasites 0-3h post-invasion after culture.
adaptation. This type of treatment exemplifies DHA’s short half-life in patients in addition to assessing parasite tolerance to a physiologically relevant dose of DHA. Supporting previous results, ARS1 possessed a higher tolerance to 700 nM DHA than PA, where a remarkable drop in parasitemia was observed. Results of this assay are represented by the survival rate (%) of parasitemia (Fig 4). PA and ARS1 were treated every 12 h (A) and 24 h (B) for up to 72 h, with 2 nM of DHA. Parasitemia was determined by microscopy of Giemsa-stained thin smears and normalized on the control parasitemia. Control parasitemia was determined from untreated PA and ARS1 strains maintained under the same conditions as the DHA treated. Means +/- SD of 3 independent experiments is shown. Significant differences of parasitemia between strains are indicated by (*) at $p < 0.05$, (**) at $p < 0.01$ and (***) at $p < 0.001$.

https://doi.org/10.1371/journal.pone.0191084.g004
PA and ARS1 that correspond to 0.51% and 6.8%, respectively. The percent survival rate is interpretable if the growth rate is \( \geq 1.5 \) (see Materials and methods). In fact, the growth rate of PA and ARS1 was 8.2 ± 4.1 and 4.7 ± 0.8, respectively (Table 2).

In this assay, the resistance to treatment appears not due to its ability to enter a dormant or quiescent state but to the ability of ARS1 to recover and overcome the effects of DHA treatment (S1 Fig).

This set of experiments show that ARS1 not only possesses quite stable characteristics in terms of IC\(_{50}\), but, even more important, the marked capability of ARS1 strain survival at a constant rate with DHA concentrations that kill 100% of parental PA strain parasites following 3 days of treatment. In addition, ARS1 survived under the RSA\(_{0-3h}\) conditions mimicking those present in plasma of drug-treated patients.

### Sensitivity of ARS1 to treatment with other antimalarials

ART are no longer used as mono-therapies to treat malaria infections and are now only prescribed in combination with a partner drugs as ACTs. Partner antimalarials are complimentary to ART and serve to compensate for the short half-lives of ARTs and improve parasite clearance by counteracting the selection of resistant parasites.

Unfortunately, artemisinin resistance has been observed in patients treated with ACTs and for this reason, it was necessary to assess ARS1 for multidrug resistance to commonly used anti-malarial drugs with longer half-lives. IC\(_{50}\) values were determined at 24, 48 and 72 h following treatment to evaluate parasite response MQ, AMQ, LMF and PPQ (Table 1). The IC\(_{50}\) concentrations of these four drugs were similar in both ARS1 and PA and parasites susceptible to each antimalarial.

Cultures were then treated with DHA and MQ, a combination commonly used in ACTs where the long half-life of MQ compensates for the fast acting but short lived DHA.

The addition of MQ greatly decreased the IC\(_{50}\) against PA, signifying an increase in sensitivity to DHA while ARS1 sensitivity remained relative stable (Fig 5). The parasitemia was assessed and multiple time points to evaluate the antimalarial effect of DHA on the cultures and the response to long-acting MQ. ARS1 resistance appeared to be selective for a DHA. The DHA IC\(_{50}\) after 72 h correspond to 0.68 ± 0.2 nM and to 2 ± 0.1 nM for ARS1 while the IC\(_{50}\) of MQ alone after 72 h correspond to 5.49 ± 0.92 nM for PA and 4.78 ± 0.6 nM for ARS1.

Finally, mutations in the Pfk13 gene have been associated with ART resistance in ex vivo assays with P. falciparum strains obtained from the eastern Greater Mekong sub-region (Cambodia, Laos and Vietnam). The most common polymorphisms include C580Y, R539T, 1543T and Y493H, so we sequenced the same regions in ARS1 and PA strains to help elucidate the underlying cause of this artemisinin phenotype. These regions were found to be identical in the two strains, eliminating this as possible causes of artemisinin resistance. Moreover, genotyping the msp1, msp2 and glurp genes, commonly used to differentiate reinfection from recrudescence in patients infected with malaria. This supports our findings that revealed no genetic

---

**Table 2. Growth rate and survival rate (%) in in vitro RSA\(_{0-3h}\) with 700 nM DHA at 72 h after ARS1 selection.**

| Strain of P. falciparum | Growth rate | Survival rate (%) | p-value vs PA |
|-------------------------|-------------|-------------------|--------------|
| PA                      | 8.2 ± 4.1   | 0.51 ± 0.46       | )            |
| ARS1                    | 4.7 ± 0.8   | 6.8 ± 0.58        | 0.011        |

Values of growth rates are expressed as non-exposed parasitemia at 72 h/initial parasitemia ± SD; values of survival rates are expressed as (DHA-exposed parasitemia at 72 h/non-exposed parasitemia 72 h) x 100 ± SD. All experiments were performed four times independently.

https://doi.org/10.1371/journal.pone.0191084.t002
Fig 5. Statistical analysis of IC$_{50}$ DHA in combination with MQ. PA and ARS1 were treated at rings stage (time 0) with 0.6, 1.25, 2.5, 5, 10 nM DHA, alone or in combination with 5 nM and 10 nM of MQ, and analysed at 24 h (A), 48 h (B) and 72 h (C). Data were normalized to the parasitemia measured at time 0 and the IC$_{50}$ was calculated using ICEstimator software. Parasitemia was measured by microscopy of Giemsa-stained thin smears. Means +/- SD from 3 independent experiments is shown. Significant differences of parasitemia between strains are indicated by (*) at p < 0.05, (**) at p < 0.01 and (***) at p < 0.001.

https://doi.org/10.1371/journal.pone.0191084.g005
diversity from these genes exists among PA and ARS1 and indicating that we have not selected a less represented strain that may have contaminated the parental strain.

The culmination of these results obtained form this study indicate that the ARS1 strain can be useful to better understand the mechanisms of ART resistance and for the evaluation of new antimalarial therapies in future studies.

**Discussion**

Through a series of treatment with low concentrations of DHA, we selected for the *P. falciparum* artemisinin resistance strain (ARS1) that arose from the parental strain PA. The ARS1 resistant phenotype was maintained under monthly sub-lethal concentrations of DHA.

The study of Brauner et al. helps to define the phenotype observed in ARS1 as a state of "tolerance", which is the capability of parasites to survive transient exposure to drugs, also without a consistent increase variation of IC$_{50}$ [56].

Alarmingly, *P. falciparum* resistance to partner drugs along with ART in combination therapies has been detected, leaving populations in South East Asia vulnerable to deadly malaria infections [49, 28, 50]. For these reasons, a better understanding of the resistance mechanism will help the selection of more effective and resistance tolerant antimalarial therapies.

In the drug discovery pipeline, identifying target genes or molecules responsible for a drug resistance phenotype is the first step in a 12–15 years process followed by high throughput screening for a candidate antimalarial compounds [57]. Despite artemisinin resistant isolates may more representative than ARS1, this could be an essential tool not only to elucidate the underlying mechanisms of artemisinin resistance but also to evaluate the efficacy of new compounds against these artemisinin resistant parasites.

To this end, we first evaluated the response of three artemisinin sensitive strains (PA, FCR3 and HB3A) to DHA, the active metabolite of all ART. Cultures were treated with low doses of DHA for 8 weeks to select for parasites demonstrating a drug tolerant phenotype. While many studies [25, 26] use high DHA concentrations (from 280 to 1200 nM) to generate resistant parasites, our method has the intended consequence of producing parasites that not enter a dormant or quiescent state, a state not demonstrated in patients. Our method intentionally prevents the accumulation of dormant parasites, using a maximum concentration of 5 nM DHA.

The artemisinin resistance phenotype of ARS1 is defined by the following features: i) adaptation to DHA is stable and can be maintained in drug-free medium for an extended period (at least 1 month); ii) a 3-fold increase in DHA IC$_{50}$ values relative to the parental strain after 72 h (2 nM in ARS1 and 0.68 nM in PA); iii) a reduced susceptibility of ARS1 to repetitive pressure with low concentrations of DHA; iv) the ability to survive after a single pulse of 700 nM (PA: 0.51%, ARS1: 6.8%); v) resistance that appears specific to DHA, with no cross-resistance to other antimalarial drugs.

It should be, anyway, noted that, although ARS1 presents a consistent 3-fold increase of the DHA IC$_{50}$ over its parental strain, the DHA IC$_{50}$s of HB3A and ARS1 are similar, therefore, the IC$_{50}$ should not be considered as an absolute index of ART resistance. On the contrary, ARS1 complies with the definition artemisinin resistant parasites, while no resistance was measurable in parental strain [32, 47]; as previously described by Witkowski, two strains with respectively ≤1% vs ≥1% of survival rate following 700 nM DHA treatment of survival rate, as PA and ARS1, are generally defined as sensitive and resistant strain.

Moreover, there was no presence of cross-resistance to other commonly used antimalarials and no increase in DHA sensitivity when combined with MQ (DHA-MQ). Despite we shouldn’t consider the IC$_{50}$ value as an ART resistance index, in this case could be an important parameter to evaluate the tolerance of ARS1 to the MQ-DHA combination. It appears
that ARS1 is selectively tolerant to DHA while maintaining its sensitivity to antimalarials present in ACTs [58, 59].

Although studies investigating the cause of artemisinin resistance are plentiful, the exact mechanism of resistance remains unclear. We postulated that a randomized molecular mutation caused the acquired resilience to DHA observed in ARS1 progeny. Genetic sequencing of the molecular markers msp1, msp2 and glurp eliminated the possibility ARS1 acquired mutations in genes that are commonly used to discriminate parasite recrudescence from re-infection alleles in patients and was consistent with ARS1 arising from PA [53]. A mutation in the recently discovered Pfk13 propeller domain was also not found. A mutation in this domain would be consistent with other reports suggesting its association with artemisinin resistance in field isolates. The lack of Pfk13 propeller mutations observed in ARS1 cannot be interpreted due to the substantial lack of knowledge pertaining to the ART’ mechanism of action and to the mutation’s heterogeneity associated with delayed parasite clearance in different geographic populations [36]. However, it is of interest to further evaluate the cause of artemisinin resistance in this case and evaluate ARS1 for a ubiquitous source of the resistance phenotype.

In conclusion, the data obtained in the present study confirm the ability of P. falciparum cultures to become less responsive to DHA. We propose the ARS1 strain as a potential tool to study artemisinin resistance mechanisms and to test new antimalarial compounds.

Supporting information

S1 Fig. Representative images of P. falciparum cultures from the RSA0-3h. PA and ARS1 were treated with 700 nM of DHA. The survival of both cultures was monitored at time 0, 24 h, 72 h and 7 days following the addition of DHA. Parasites were monitored by Diff-Quick stained smears light microscopy using a 100x oil-immersion objective.

(TIFF)

Acknowledgments

The authors would like to thank Banca del sangue C/O Ospedale Molinette in Torino for the collection of human blood samples.

We also thank Dr. Schwarzer, Dr. Mandili and Dr. Khadjavi for critically revising the manuscript.

Author Contributions

Conceptualization: Serena De Lucia, Francesco Turrini.

Data curation: Serena De Lucia, Ioannis Tsamesidis, Maria Carmina Pau.

Formal analysis: Serena De Lucia.

Funding acquisition: Francesco Turrini.

Methodology: Serena De Lucia.

Project administration: Serena De Lucia.

Supervision: Francesco Turrini.

Visualization: Antonella Pantaleo.

Writing – original draft: Serena De Lucia, Francesco Turrini.

Writing – review & editing: Serena De Lucia, Kristina R. Kesely.
References

1. White NJ, Pukrittayakamee S, Hien TT, Faiz MA, Mokuolu OA, Dondorp AM. Malaria. The Lancet. 2014; 383(9818):723–35

2. World Health Organization. World Malaria Report 2017. WHO, Geneve. 2017. http://apps.who.int/iris/bitstream/10665/259492/1/9789241565523-eng.pdf?ua=1

3. Pandey AV, Tekwani BL, Singh RL, Chauhan VS. Artemisinin, an endoperoxide antimalarial, disrupts the hemoglobin catabolism and heme detoxification systems in malarial parasite. J Biol Chem. 1999; 274(27):19383–19388 PMID: 10383451

4. del Pilar Crespo M, Avery TD, Hanssen E, Fox E, Robinson TV, Valente P et al. Artemisinin and a series of novel endoperoxide antimalarials exert early effects on digestive vacuole morphology. Antimicrob Agents Chemother. 2008; 52(1):98–109 https://doi.org/10.1128/AAC.00609-07 PMID: 19378190

5. Sullivan DJ Jr. Timing is everything for artemisinin action. Proc Natl Acad Sci U S A. 2013; 110 (13):4866–4867 https://doi.org/10.1073/pnas.1301607110 PMID: 23493560

6. Fairhurst RM, Nayyar GM, Breman JG, Hallet R, Vennerstrom JL, Duong S, Ringwald P, Wellems TE, Plowe CV, Dondorp AM. Artemisinin-Resistant malaria: Research challenges, opportunities, and Public Health implications. Am J Trop Med Hyg. 2012 Aug 1; 87(2):231–241 https://doi.org/10.4269/ajtmh.2012.12-0025 PMID: 22855752

7. Ho WE, Peh HY, Chan TK, Wong WS. Artemisinins: pharmacological actions beyond anti-malarial. Pharmacol Ther. 2014; 142(1):126–139 https://doi.org/10.1016/j.pharmthera.2013.12.001 PMID: 24316259

8. Giao PT, Binh TQ, Kager PA, Long HP, Van Thang N, Van Nam N et al. Artemisinin for the treatment of uncomplicated falciparum malaria: is there a place for monotherapy? Am J Trop Med Hyg. 2001; 65 (6):690–695 PMID: 11791958

9. Sinclair D, Zani B, Donegan S, Olliaro P, Garner P. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev. 2009;(3):CD007483 https://doi.org/10.1002/14651858.CD007483.pub2 PMID: 19588433

10. Slater HC, Griffin JT, Ghani AC, Okell LC. Assessing the potential impact of artemisinin and partner drug resistance in sub-Saharan Africa. Malar J. 2016 Jan 6; 15:10 https://doi.org/10.1186/s12936-015-1075-7 PMID: 26739092

11. Mita T, Tanabe K. Evolution of Plasmodium falciparum drug resistance: implications for the development and containment of artemisinin resistance. Jpn J Infect Dis. 2012; 65(6):465–475 PMID: 23183197

12. Krishna S, Kremsner PG. Antidogmatic approaches to artemisinin resistance: reappraisal as treatment failure with artemisinin combination therapy. Trends of Parasitol. 2013 Jul; 29(7):313–7

13. World Health Organization. Update on artemisinin and ACT resistance. WHO, Geneve. 2015. http://www.who.int/malaria/publications/atoz/update-artemisinin-resistance-sep2015/en/

14. Fairhurst RM, Dondorp AM. Artemisinin-resistant Plasmodium falciparum malaria. Microbiol Spectr. 2016 Jun; 4(3). https://doi.org/10.1128/microbiolspec.EI10-0013-2016 PMID: 27337450

15. Taylor SM, Juliano JJ, Meshnick SR. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009; 361(18):1807

16. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009; 361(18):1807

17. White NJ, Hien TT, Nosten FH. A brief history of Qinghaosu. Trend Parasitol. 2015; 31(12): 607–610

18. Kavishe RA, Koenderink JB, Alifrangis M. Oxidative stress in malaria and Artemisinin combination therapy: Pros and Cons. FEBS J. 2017 May 3

19. Cui L, Su X. Discovery, mechanisms of action and combination therapy of Artemisinin. Expert Rev Anti Infect Ther. 2009 Oct; 7(8):999–1013 https://doi.org/10.1586/eri.09.68 PMID: 19803708

20. Akide-Ndunge OB, Tambini E, Giribaldi G, McMillan PJ, Muller S, Arese P et al. Co-ordinated stage-dependent enhancement of Plasmodium falciparum antioxidant enzymes and heat shock protein expression in parasites growing in oxidatively stressed or G6PD-deficient red blood cells. Malar J. 2009; 8:113 https://doi.org/10.1186/1475-2875-8-113 PMID: 19480682

21. World Health Organization. Weekly epidemiological record. World Health Organization, Geneve. 2014. http://www.who.int/wer/2014/wer8929.pdf?ua=1

22. Nzila A, Mwai L. In vitro selection of Plasmodium drug-resistant parasite lines. J Antimicrob Chemother. 2009; 65(3):390–398.

23. Witkowski B, Leilievre J, Barragan MJL, Laurent V, Su XZ, Berry A et al. Increased tolerance to artemisinin in Plasmodium falciparum is mediated by a quiescence mecha-nism. Antimicrob. Agents Chemother. 2010; 54(5):1872–1877 https://doi.org/10.1128/AAC.01636-09 PMID: 20160058
24. Jambou R, Legrand E, Niang M, Khim N, Lim P, Volney B et al. Resistance of Plasmodium falciparum field isolated to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet. 2005 Dec 3; 366(9501): 1960–3 https://doi.org/10.1016/S0140-6736(05)67787-2 PMID: 16325698

25. Hott A, Tucker MS, Casandera D, Sparks K, Kyle DE. Fitness of artemisinin-resistant Plasmodium falciparum in vitro. J Antimicrob Chemother. 2015; 70:2787–2796 https://doi.org/10.1093/jac/dkv199 PMID: 26203183

26. Tucker MS, Mutka T, Sparks K, Patel J, Kyle DE. Phenotypic and genotypic analysis of in vitro-selected artemisinin-resistant progeny of Plasmodium falciparum. Antimicrob Agents Chemother. 2012; 56 (1):302–14 https://doi.org/10.1128/AAC.00900-11 PMID: 22083467

27. Noedl H, Socheat D, Satimai W. Artemisinin-resistant malaria in Asia. N Engl J Med. 2009; 361(5):540–1 https://doi.org/10.1056/NEJMoa0900231 PMID: 19641219

28. Cui L, Wang Z, Miao J, Chandra R, Jiang Hm Su XZ, Cui L. Mechanisms of in vitro resistance to dihydroartemisinin in Plasmodium falciparum. Mol Microbiol. 2012; 86(1): 111–128 https://doi.org/10.1111/j.1365-2958.2012.08180.x PMID: 22812578

29. Witkowski B, Berry A, Benoit-Vical F. Resistance to antimalarial compounds: Methods and applications. Drug Resist Updat. 2009; 12(1–2):42–50 https://doi.org/10.1016/j.drup.2009.01.001 PMID: 19285915

30. Cui L, Su XZ. Discovery, mechanisms of action and combination therapy of artemisinin. Expert Rev Anti Infect Ther. 2009; 7:999–1013 https://doi.org/10.1586/eri.09.68 PMID: 19803708

31. Cui L, Wang Z, Jiang H, Parker D, Wang H, Su XZ et al. Lack of association of the S769N mutation in Plasmodium falciparum SERCA (PfATP6) with resistance to artemisinins. Antimicrob Agents Chemother. 2012; 56:2546–2552 https://doi.org/10.1128/AAC.05943-11 PMID: 22354307

32. Ariey F, Witkowski B, Amarantunga C, Beghain J, Langlois AC, Khim N et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 2014; 505(7481):50–55 https://doi.org/10.1038/nature12876 PMID: 24352242

33. Teuscher F, Gatton ML, Chen N, Peters J, Kyle DE, Cheng Q. Artemisinin-induced dormancy in Plasmodium falciparum: duration, recovery rates, and implications in treatment failure. J Infect Dis. 2010 Nov 1; 202(9):1362–8 https://doi.org/10.1086/656476 PMID: 20863228

34. Wang Z, Shrestha S, Li X, Miao J, Yuan L, Cabrera M et al. Prevalence of k13-propeller polymorphisms in Plasmodium falciparum from China-Myanmar border in 2007–2012. Malar J. 2015; 14:168 https://doi.org/10.1186/s12936-015-0672-9 PMID: 25927592

35. Strainer J, Gnadig NF, Witkowski B, Amarantunga C, Duru V, Ramadani AP et al. Drug resistance. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science 2015; 347(6220):428–431 https://doi.org/10.1126/science.1260867 PMID: 25502314

36. Ménard D, Khim N, Beghain J, Adegnika AA, Shaful-Alam M, Amodu O et al. A worldwide map of Plasmodium falciparum K13-propeller polymorphisms. N Engl J Med. 2016; 374(25):2453–2464 https://doi.org/10.1056/NEJMc0900231 PMID: 19641219

37. Mbengue A, Bhattacharjee S, Pandharikar T, Liu H, Estiu G, Stahelin RV et al. A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria. Nature 2015; 520(7549):683–687 https://doi.org/10.1038/nature14412 PMID: 25874676

38. Bhattacharjee S, Speicher KD, Stahelin RV, Speicher DW, Haldar K. Pf(3)P-independent and -dependent pathways function together in a vacuolar translocation sequence to target malarial proteins to the host erythrocyte. Mol Biochem Parasitol. 2012; 185:106–113 https://doi.org/10.1016/j.molbiopara.2012.07.004 PMID: 22828070

39. Bhattacharjee S, Stahelin RV, Speicher KD Speicher DW, Haldar K. Endoplasmic reticulum Pf(3)P lipid binding targets malaria proteins to the host cell. Cell 2012; 148(1–2):201–212 https://doi.org/10.1016/j.cell.2011.10.051 PMID: 22265412

40. Taylor SM, Parobek CM, DeConti DK, Kayentao K, Coulibaly SO, Greenwood BM et al. Absence of putative artemisinin resistance mutations among Plasmodium falciparum in Sub-Saharan Africa: a molecular epidemiologic study. J Infect Dis. 2015; 211(5):680–8 https://doi.org/10.1093/infdis/jiu467 PMID: 25180240

41. Balikagala B, Mita T, Ikeda M, Sakurai M, Yatsushiro S, Takahashi N et al. Absence of in vivo selection for K13 mutations after artemether-lumefantin treatment in Uganda. Malar J. 2017 Jan 9; 16(1):23 https://doi.org/10.1186/s12936-016-1663-1 PMID: 28068997

42. Fandeur T, Bonnefoy S, Mercereau-Puijalon O. In vivo and in vitro derived Palo Alto lines of Plasmodium falciparum are genetically unrelated. Mol Biochem Parasitol. 1991 Aug; 47(2):167–78 PMID: 1944415

43. Bhasin VK, Trager W. Gameteocyte-forming and non-gameteocyte-forming clones of Plasmodium falciparum. Am J Trop Med Hyg. 1984 Jul; 33(4):534–7 PMID: 6383092

44. Kramer KJ, Kan SC, Siddiquil WA. Concentration of Plasmodium falciparum-infected erythrocytes density gradient centrifugation in Percoll. J Parasitol. 1982 Apr; 68(2):336–7 PMID: 6281409
45. Lambros C, Vanderberg JP. Synchronization of Plasmodium falciparum erythrocytic stages in culture. J Parasitol. 1979; 65(3):418–420 PMID: 383936

46. Worldwide Antimalarial Resistance Network. Standard operating procedure Ring Stage survival Assays. 11 September 2013. http://www.wwarn.org/sites/default/files/INV10-Standard-Operating-Procedure-Ring-Stage-Survival-Assays.pdf.

47. Witkowski B, Amaratunga C, Khim N, Srieng S, Chim P, Kim S et al. Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies. Lancet Infect Dis. 2013; 13(12):1043–1049 https://doi.org/10.1016/S1473-3099(13)70252-4 PMID: 24035558

48. Kite WA, Melendez-Muniz VA, Moraes Barros RR, Wellems TE, Sa JM. Alternative methods for the Plasmodium falciparum artemisinin ring-stage survival assay with increased simplicity and parasite stage-specificity. Malar J. 2016; 15:94 https://doi.org/10.1186/s12936-016-1148-2 PMID: 26888201

49. Ding XC, Ubben D, Wells TNC. A framework for assessing the risk of resistance for antimalarials in development. Malar J. 2012; 11: 292 https://doi.org/10.1186/1475-2875-11-292 PMID: 22913649

50. Kaddouri H, Nakache S, Houzé S, Mentré F, Le Bras J. Assessment of the Drug Susceptibility of Plasmodium falciparum Clinical Isolates from Africa by Using a Plasmodium Lactate Dehydrogenase Immunodetection Assay and an Inhibitory Maximum Effect Model for Precise Measurement of the 50-Percent Inhibitory Concentration. Antimicrob Agents Chemother. 2006 Oct; 50(10): 3343–3349 https://doi.org/10.1128/AAC.00367-06 PMID: 17005815

51. Le Nagard H, Vincent C, Mentré F, Le Bras J. Online analysis of in vitro resistance to antimalarial drugs through nonlinear regression. Comput Methods Programs Biomed. 2011 Oct; 104(1):10–8 https://doi.org/10.1016/j.cmpb.2010.08.003 PMID: 20828858

52. Miller S.A., Dykes D.D., and Polesky H.F., A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res, 1988. 16(3): p. 1215. PMID: 3344216

53. Snounou G. Genotyping of Plasmodium spp. Nested PCR. Methods Mol Med. 2002; 72:103–116 https://doi.org/10.1385/1-59259-271-6:103 PMID: 12125106

54. Viriyakosol S, Siripoon N, Petcharapirat C, Petcharapirat P, Jarra W, Thaithong S et al. Genotyping of Plasmodium falciparum isolates by the polymerase chain reaction and potential uses in epidemiological studies. Bull World Health Organ. 1995; 73(1):85–95 PMID: 7704931

55. Parapini S, Olliaro P, Navaratnam V, Taramelli D, Basilico N. Stability of the antimalarial drug dihydroartemisinin under physiologically relevant conditions: implications for clinical treatment and pharmacokinetic and in vitro assays. Antimicrob Agents Chemother. 2015 Jul; 59(7):4046–52 https://doi.org/10.1128/AAC.00183-15 PMID: 25918150

56. Brauner A, Fridman O, Gegen O, Balaban NQ. Distinguishing between resistance, tolerance and persistence to antibiotic treatment. Nat Rev Microbiol. 2016; 14(5):320–30 https://doi.org/10.1038/nrmicro.2016.34 PMID: 27080241

57. Roses AD. Pharmacogenetics in drug discovery and development: a translational perspective. Nat Rev Drug Discov. 2008 Oct; 7(10):807–17 https://doi.org/10.1038/nrd2593 PMID: 18806753

58. Parobek CM, Parr JB, Brazeau NF, Lon C, Chaorattanakawee S et al. Partner-Drug Resistance and Population Substructuring of Artemisinin-Resistant Plasmodium falciparum in Cambodia. Genome Biol Evol. 2017 Jun; 9(6): 1673–1686 https://doi.org/10.1093/gbe/evx126 PMID: 28854635

59. Imwong M, Jindakhad T, Kunasol C, Sutawong K, Vejakama P, Dondorp AM. An outbreak of artemisinin resistant falciparum malaria in Eastern Thailand. Sci Rep. 2015; 5: 17412 https://doi.org/10.1038/srep17412 PMID: 26616851